Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201
Head And Neck Cancer
Explore 142 assets in Head And Neck Cancer →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Rapa Therapeutics LLC
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05144698CT.gov RAPA-201 Therapy of Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Head And Neck Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201 (this asset) | Rapa Therapeutics LLC | P1/2 | CC · 43 |
| Nepenthe | Instituto Nacional de Cancer, Brazil | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | ImmunityBio, Inc. | P3 | BB |
| Lidocaine | Instituto Nacional de Cancer, Brazil | P3 | BB |
| Carboplatin | Rapa Therapeutics LLC | P3 | BB |
| Nivestim | University of Colorado, Denver | P2 | BB |
| Cyclophosphamide | Zelluna Immunotherapy AS | P3 | BB |
| Pembrolizumab | Thomas Jefferson University | P3 | BB |
| Epirubicin | Thomas Jefferson University | P3 | BB |
+41 more in the Head And Neck Cancer cohort
Other indications for Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P2 | B · 58 |
| Metastatic Melanoma | — | P2 | CCC · 53 |
| Nasopharyngeal Squamous Cell Carcinoma | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201 in Head And Neck Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-rapamycin-resistant-th1tc1-cells-rapa-201-head-and-neck-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →